西班牙成人丙肝筛查的医疗价值数据集

数据集获取（Figshare）

• 源站标题：Healthcare value of implementing hepatitis C screening in the adult general population in Spain
• DOI：10.1371/journal.pone.0208036
• 发布日期：2018-11-28
• 文件数：5 个
• 文件总体积：307.77 KB
• 源站页面：https://plos.figshare.com/articles/dataset/Healthcare_value_of_implementing_hepatitis_C_screening_in_the_adult_general_population_in_Spain/7396115

命令行下载

curl -L -o "pone.0208036.s001.docx" "https://ndownloader.figshare.com/files/13682186"
curl -L -o "pone.0208036.s002.docx" "https://ndownloader.figshare.com/files/13682189"
curl -L -o "pone.0208036.s003.tif" "https://ndownloader.figshare.com/files/13682192"
curl -L -o "pone.0208036.s004.docx" "https://ndownloader.figshare.com/files/13682195"
curl -L -o "pone.0208036.s005.docx" "https://ndownloader.figshare.com/files/13682198"

文件清单

• pone.0208036.s001.docx（13.29 KB）
• pone.0208036.s002.docx（16.60 KB）
• pone.0208036.s003.tif（246.52 KB）
• pone.0208036.s004.docx（17.52 KB）
• pone.0208036.s005.docx（13.85 KB）

文件总体积 307.77 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Background
Elimination of hepatitis C virus (HCV) infection requires high diagnostic rates and universal access to treatment. Around 40% of infected individuals are unaware of their infection, which indicates that effective screening strategies are needed. We analyzed the efficiency (incremental cost-utility ratio, ICUR) of 3 HCV screening strategies: a) general population of adults, b) high-risk groups, and c) population with the highest anti-HCV prevalence plus high-risk groups.
Methods
An analytical decision model, projecting progression of the disease over a lifetime, was used to establish the candidate population for HCV screening. HCV data were obtained from the literature: anti-HCV prevalence (0.56%-1.54%), viremic patients (31.5%), and percentage of undiagnosed persons among those with viremia (35%). It was assumed that most patients would be treated and have HCV therapy response (98% SVR); transition probabilities, utilities, and disease management annual costs were obtained from the literature. Efficiency over the life of patients under the National Health System perspective was measured as quality-adjusted life years (QALY) and total cost (screening, diagnosis, pharmacological and disease management). A discount rate of 3% was applied to costs and outcomes.
Results
Screening of the adult population would identify a larger number of additional chronic hepatitis C cases (N = 52,694) than screening the highest anti-HCV prevalence population plus high-risk groups (N = 42,027) or screening high-risk groups (N = 26,128). ICUR for the general population vs. high-risk groups was €8914/QALY gained per patient (€18,157 incremental cost and 2.037 QALY). ICUR for the general population vs. population with highest anti-HCV prevalence plus high-risk groups was €7,448/QALY gained per patient (€7,733 incremental cost and 1.038 QALY). These ICUR values are below the accepted efficiency threshold (€22,000-€30,000).
Conclusion
HCV screening and treatment of the general adult population is cost-effective compared to screening of high-risk groups or the population with the highest anti-HCV prevalence plus high-risk groups.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0208036（source: https://plos.figshare.com/articles/dataset/Healthcare_value_of_implementing_hepatitis_C_screening_in_the_adult_general_population_in_Spain/7396115）。